A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Bern-Thomas Nyang'waCatherine BerryEmil KazounisIlaria MottaNargiza ParpievaZinaida TigayVarvara SolodovnikovaIrina LiverkoRonelle MoodliarMatthew DoddNosipho NgubaneMohammed RassoolTimothy D McHughMelvin SpigelmanDavid A J MooreKoert RitmeijerPhilipp du CrosKatherine Fieldingnull nullPublished in: The New England journal of medicine (2022)
In patients with rifampin-resistant pulmonary tuberculosis, a 24-week, all-oral regimen was noninferior to the accepted standard-care treatment, and it had a better safety profile. (Funded by Médecins sans Frontières; TB-PRACTECAL ClinicalTrials.gov number, NCT02589782.).